|
1
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
The Lancet: Lung cancer: Some progress,
but still a lot more to do. Lancet. 394:18802019. View Article : Google Scholar
|
|
4
|
Ganti AK, Klein AB, Cotarla I, Seal B and
Chou E: Update of incidence, prevalence, survival, and initial
treatment in patients with non-small cell lung cancer in the US.
JAMA Oncol. 7:1824–1832. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Leiter A, Veluswamy RR and Wisnivesky JP:
The global burden of lung cancer: Current status and future trends.
Nat Rev Clin Oncol. 20:624–639. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pallis AG and Syrigos KN: Lung cancer in
never smokers: Disease characteristics and risk factors. Crit Rev
Oncol Hematol. 88:494–503. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Roth GA, Mensah GA, Johnson CO, Addolorato
G, Ammirati E, Baddour LM, Barengo NC, Beaton AZ, Benjamin EJ,
Benziger CP, et al: Global burden of cardiovascular diseases and
risk factors, 1990–2019: Update from the GBD 2019 study. J Am Coll
Cardiol. 76:2982–3021. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Arima H, Barzi F and Chalmers J: Mortality
patterns in hypertension. J Hypertens. 29:S3–S7. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
NCD Risk Factor Collaboration (NCD-RisC),
. Worldwide trends in blood pressure from 1975 to 2015: A pooled
analysis of 1479 population-based measurement studies with 19.1
million participants. Lancet. 389:37–55. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
van Kruijsdijk RC, van der Graaf Y,
Peeters PH and Visseren FL; Second Manifestations of ARTerial
disease (SMART) study group, : Cancer risk in patients with
manifest vascular disease: Effects of smoking, obesity, and
metabolic syndrome. Cancer Epidemiol Biomarkers Prev. 22:1267–1277.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hatlen P, Langhammer A, Carlsen SM,
Salvesen O and Amundsen T: Self-reported cardiovascular disease and
the risk of lung cancer, the HUNT study. J Thorac Oncol. 9:940–946.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sorensen HT, Svaerke C, Farkas DK,
Christiansen CF, Pedersen L, Lash TL, Prandoni P and Baron JA:
Superficial and deep venous thrombosis, pulmonary embolism and
subsequent risk of cancer. Eur J Cancer. 48:586–593. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Stocks T, Van Hemelrijck M, Manjer J,
Bjørge T, Ulmer H, Hallmans G, Lindkvist B, Selmer R, Nagel G,
Tretli S, et al: Blood pressure and risk of cancer incidence and
mortality in the Metabolic Syndrome and Cancer Project.
Hypertension. 59:802–810. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Buck C and Donner A: Cancer incidence in
hypertensives. Cancer. 59:1386–1390. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang C, Lu D, Cronin-Fenton D, Huang C,
Liew Z, Wei D, Qin G, Yu Y and Li J: Cardiovascular disease and
risk of lung cancer incidence and mortality: A nationwide matched
cohort study. Front Oncol. 12:9509712022. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lindgren A, Pukkala E, Nissinen A and
Tuomilehto J: Blood pressure, smoking, and the incidence of lung
cancer in hypertensive men in North Karelia, Finland. Am J
Epidemiol. 158:442–447. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Peeters PH, van Noord PA, Hoes AW and
Grobbee DE: Hypertension, antihypertensive drugs, and mortality
from cancer among women. J Hypertens. 16:941–947. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lee SY, Kim MT, Jee SH and Im JS: Does
hypertension increase mortality risk from lung cancer? A
prospective cohort study on smoking, hypertension and lung cancer
risk among Korean men. J Hypertens. 20:617–622. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Huff MO, Todd SL, Smith AL, Elpers JT,
Smith AP, Murphy RD, Bleser-Shartzer AS, Hoerter JE, Radde BN and
Klinge CM: Arsenite and cadmium activate MAPK/ERK via membrane
estrogen receptors and G-protein coupled estrogen receptor
signaling in human lung adenocarcinoma cells. Toxicol Sci.
152:62–71. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hartwig A, Asmuss M, Ehleben I, Herzer U,
Kostelac D, Pelzer A, Schwerdtle T and Bürkle V: Interference by
toxic metal ions with DNA repair processes and cell cycle control:
molecular mechanisms. Environ Health Perspect. 110 (Suppl):797–799.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kim HS, Kim YJ and Seo YR: An overview of
carcinogenic heavy metal: Molecular toxicity mechanism and
prevention. J Cancer Prev. 20:232–240. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Caffo M, Caruso G, Fata GL, Barresi V,
Visalli M, Venza M and Venza I: Heavy metals and epigenetic
alterations in brain tumors. Curr Genomics. 15:457–463. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Coyle YM, Minahjuddin AT, Hynan LS and
Minna JD: An ecological study of the association of metal air
pollutants with lung cancer incidence in Texas. J Thorac Oncol.
1:654–661. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Satarug S, Nishijo M, Ujjin P,
Vanavanitkun Y and Moore MR: Cadmium-induced nephropathy in the
development of high blood pressure. Toxicol Lett. 157:57–68. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Swaddiwudhipong W, Mahasakpan P,
Limpatanachote P and Krintratun S: Correlations of urinary cadmium
with hypertension and diabetes in persons living in
cadmium-contaminated villages in northwestern Thailand: A
population study. Environ Res. 110:612–616. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Valera B, Dewailly E and Poirier P:
Environmental mercury exposure and blood pressure among Nunavik
Inuit adults. Hypertension. 54:981–986. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Huang Z: Association between blood lead
level with high blood pressure in US (NHANES 1999–2018). Front
Public Health. 10:8363572022. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Vaziri ND and Sica DA: Lead-induced
hypertension: Role of oxidative stress. Curr Hypertens Rep.
6:314–320. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bunderson M, Coffin JD and Beall HD:
Arsenic induces peroxynitrite generation and cyclooxygenase-2
protein expression in aortic endothelial cells: Possible role in
atherosclerosis. Toxicol Appl Pharmacol. 184:11–18. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
da Cunha Martins A, Jr, Carneiro MFH,
Grotto D, Adeyemi JA and Barbosa F Jr: Arsenic, cadmium, and
mercury-induced hypertension: Mechanisms and epidemiological
findings. J Toxicol Environ Health B Crit Rev. 21:61–82. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Torres AD, Rai AN and Hardiek ML: Mercury
intoxication and arterial hypertension: Report of two patients and
review of the literature. Pediatrics. 105:E342000. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Travis WD, Brambilla E, Nicholson AG,
Yatabe Y, Austin JHM, Beasley MB, Chirieac LR, Dacic S, Duhig E,
Flieder DB, et al: The 2015 World health organization
classification of lung tumors: Impact of genetic, clinical and
radiologic advances since the 2004 classification. J Thorac Oncol.
10:1243–1260. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gandevia B and Tovell A: Declaration of
Helsinki. Med J Aust. 2:320–321. 1964. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Williams B, Mancia G, Spiering W, Rosei
EA, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak
A, et al: 2018 ESC/ESH guidelines for the management of arterial
hypertension. Eur Heart J. 39:3021–3104. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Li H and Durbin R: Fast and accurate
long-read alignment with Burrows-Wheeler transform. Bioinformatics.
26:589–595. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
McKenna A, Hanna M, Banks E, Sivachenko A,
Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel S, Daly
M and DePristo MA: The genome analysis toolkit: A MapReduce
framework for analyzing next-generation DNA sequencing data. Genome
Res. 20:1297–1303. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lai Z, Markovets A, Ahdesmaki M, Chapman
B, Hofmann O, McEwen R, Johnson J, Dougherty B, Barrett JC and Dry
JR: VarDict: A novel and versatile variant caller for
next-generation sequencing in cancer research. Nucleic Acids Res.
44:e1082016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wang K, Li M and Hakonarson H: ANNOVAR:
Functional annotation of genetic variants from high-throughput
sequencing data. Nucleic Acids Res. 38:e1642010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yu G, Wang LG, Han Y and He QY:
clusterProfiler: An R package for comparing biological themes among
gene clusters. OMICS. 16:284–287. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Qu S, Liu J, Luo J, Huang Y, Shi W, Wang B
and Cai X: A rapid and highly sensitive portable chemiluminescent
immunosensor of carcinoembryonic antigen based on immunomagnetic
separation in human serum. Anal Chim Acta. 766:94–99. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Gong X and Zhang H: Diagnostic and
prognostic values of anti-elicobacter pylori antibody combined with
serum CA724, CA19 and CEA for young patients with early gastric
cancer. J Clin Lab Anal. 34:e232682020. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhao S, Cao S, Luo L, Zhang Z, Yuan G,
Zhang Y, Yang Y, Guo W, Wang L, Chen F, et al: A preliminary
investigation of metal element profiles in the serum of patients
with bloodstream infections using inductively-coupled plasma mass
spectrometry (ICP-MS). Clin Chim Acta. 485:323–332. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Mayakonda A, Lin DC, Assenov Y, Plass C
and Koeffler HP: Maftools: Efficient and comprehensive analysis of
somatic variants in cancer. Genome Res. 28:1747–1756. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Riely GJ, Wood DE, Ettinger DS, Aisner DL,
Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, et
al: Non-small cell lung cancer, version 4.2024, NCCN clinical
practice guidelines in oncology. J Natl Compr Canc Netw.
22:249–274. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Guo H, Zhang J, Qin C, Yan H, Liu T, Hu H,
Tang S, Tang S and Zhou H: Biomarker-targeted therapies in
non-small cell lung cancer: Current status and perspectives. Cells.
11:32002022. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Pao W, Wang TY, Riely GJ, Miller VA, Pan
Q, Ladanyi M, Zakowski MF, Heelan RT, Kris MG and Varmus HE: KRAS
mutations and primary resistance of lung adenocarcinomas to
gefitinib or erlotinib. PLoS Med. 2:e172005. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wang M, Herbst RS and Boshoff C: Toward
personalized treatment approaches for non-small-cell lung cancer.
Nat Med. 27:1345–1356. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Tan AC and Tan DSW: Targeted therapies for
lung cancer patients with oncogenic driver molecular alterations. J
Clin Oncol. 40:611–625. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Hamnvik OP, Choueiri TK, Turchin A, McKay
RR, Goyal L, Davis M, Kaymakcalan MD and Williams JS: Clinical risk
factors for the development of hypertension in patients treated
with inhibitors of the VEGF signaling pathway. Cancer. 121:311–319.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Essa H, Dobson R, Wright D and Lip GYH:
Hypertension management in cardio-oncology. J Hum Hypertens.
34:673–681. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Chen F, Chen N, Yu Y and Cui J: Efficacy
and safety of epidermal growth factor receptor (EGFR) inhibitors
plus antiangiogenic agents as first-line treatments for patients
with advanced EGFR-mutated non-small cell lung cancer: A
meta-analysis. Front Oncol. 10:9042020. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
GBD 2019 Respiratory Tract Cancers
Collaborators, . Global, regional, and national burden of
respiratory tract cancers and associated risk factors from 1990 to
2019: A systematic analysis for the Global Burden of Disease Study
2019. Lancet Respir Med. 9:1030–1049. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Cheng ES, Weber MF, Steinberg J, Canfell K
and Yu XQ: Evaluating risk factors for lung cancer among
never-smoking individuals using two Australian studies. J Cancer
Res Clin Oncol. 148:2827–2840. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Rivera GA and Wakelee H: Lung cancer in
never smokers. Adv Exp Med Biol. 893:43–57. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Zhang T, Joubert P, Ansari-Pour N, Zhao W,
Hoang PH, Lokanga R, Moye AL, Rosenbaum J, Gonzalez-Perez A,
Martínez-Jiménez F, et al: Genomic and evolutionary classification
of lung cancer in never smokers. Nat Genet. 53:1348–1359. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Zhang XC, Wang J, Shao GG, Wang Q, Qu X,
Wang B, Moy C, Fan Y, Albertyn Z, Huang X, et al: Comprehensive
genomic and immunological characterization of Chinese non-small
cell lung cancer patients. Nat Commun. 10:17722019. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Ha SY, Choi SJ, Cho JH, Choi HJ, Lee J,
Jung K, Irwin D, Liu X, Lira ME, Mao M, et al: Lung cancer in
never-smoker Asian females is driven by oncogenic mutations, most
often involving EGFR. Oncotarget. 6:5465–5474. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Li C, Fang R, Sun Y, Han X, Li F, Gao B,
Iafrate AJ, Liu XY, Pao W, Chen H and Ji H: Spectrum of oncogenic
driver mutations in lung adenocarcinomas from East Asian never
smokers. PLoS One. 6:e282042011. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Aboumsallem JP, Moslehi J and de Boer RA:
Reverse cardio-oncology: Cancer development in patients with
cardiovascular disease. J Am Heart Assoc. 9:e0137542020. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Hao B, Oehlmann S, Sowa ME, Harper JW and
Pavletich NP: Structure of a Fbw7-Skp1-cyclin E complex:
Multisite-phosphorylated substrate recognition by SCF ubiquitin
ligases. Mol Cell. 26:131–143. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Zhou Z, He C and Wang J: Regulation
mechanism of Fbxw7-related signaling pathways (Review). Oncol Rep.
34:2215–2224. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Fan J, Bellon M, Ju M, Zhao L, Wei M, Fu L
and Nicot C: Clinical significance of FBXW7 loss of function in
human cancers. Mol Cancer. 21:872022. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Yeh CH, Bellon M and Nicot C: FBXW7: A
critical tumor suppressor of human cancers. Mol Cancer. 17:1152018.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Gasca J, Flores ML, Giraldez S,
Ruiz-Borrego M, Tortolero M, Romero F, Japón MA and Sáez C: Loss of
FBXW7 and accumulation of MCL1 and PLK1 promote paclitaxel
resistance in breast cancer. Oncotarget. 7:52751–52765. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Chen S, Leng P, Guo J and Zhou H: FBXW7 in
breast cancer: Mechanism of action and therapeutic potential. J Exp
Clin Cancer Res. 42:2262023. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Chen S, Lin J, Zhao J, Lin Q, Liu J, Wang
Q, Mui R and Ma L: FBXW7 attenuates tumor drug resistance and
enhances the efficacy of immunotherapy. Front Oncol.
13:11472392023. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Wang W, Jiang K, Liu X, Li J, Zhou W, Wang
C, Cui J and Liang T: FBXW7 and human tumors: Mechanisms of drug
resistance and potential therapeutic strategies. Front Pharmacol.
14:12780562023. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Shen W, Zhou Q, Peng C, Li J, Yuan Q, Zhu
H, Zhao M, Jiang X, Liu W and Ren C: FBXW7 and the hallmarks of
cancer: Underlying mechanisms and prospective strategies. Front
Oncol. 12:8800772022. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Xing L, Xu L, Zhang Y, Che Y, Wang M, Shao
Y, Qiu D, Yu H, Zhao F and Zhang J: Recent insight on regulations
of FBXW7 and its role in immunotherapy. Front Oncol. 12:9250412022.
View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Yokobori T, Yokoyama Y, Mogi A, Endoh H,
Altan B, Kosaka T, Yamaki E, Yajima T, Tomizawa K, Azuma Y, et al:
FBXW7 mediates chemotherapeutic sensitivity and prognosis in
NSCLCs. Mol Cancer Res. 12:32–37. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Wang Q, Chai L, Zhang Q, Wang J, Liu J,
Chen H, Wang Y, Chen Y, Shen N, Xie X and Li M: Induction of GLI1
by miR-27b-3p/FBXW7/KLF5 pathway contributes to pulmonary arterial
hypertension. J Mol Cell Cardiol. 171:16–29. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Frassanito MA, Desantis V, Di Marzo L,
Craparotta I, Beltrame L, Marchini S, Annese T, Visino F, Arciuli
M, Saltarella I, et al: Bone marrow fibroblasts overexpress miR-27b
and miR-214 in step with multiple myeloma progression, dependent on
tumour cell-derived exosomes. J Pathol. 247:241–253. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Ruiz EJ, Diefenbacher ME, Nelson JK,
Sancho R, Pucci F, Chakraborty A, Moreno P, Annibaldi A, Liccardi
G, Encheva V, et al: LUBAC determines chemotherapy resistance in
squamous cell lung cancer. J Exp Med. 216:450–465. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Qian H, Li G, Luo Y, Fu X, Wan S, Mao X,
Yin W, Min Z, Jiang J, Yi G and Tan X: Relationship between
occupational metal exposure and hypertension risk based on
conditional logistic regression analysis. Metabolites. 12:12592022.
View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Zhang Z, Zhao S, Wu H, Qin W, Zhang T,
Wang Y, Tang Y, Qi S, Cao Y and Gao X: Cross-sectional study:
Relationship between serum trace elements and hypertension. J Trace
Elem Med Biol. 69:1268932022. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Xu J, White AJ, Niehoff NM, O'Brien KM and
Sandler DP: Airborne metals exposure and risk of hypertension in
the Sister Study. Environ Res. 191:1101442020. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
El-Kersh K, Hopkins CD, Wu X, Rai SN, Cave
MC, Smith MR, Go YM, Jones DP, Cai L and Huang J: Metallomics in
pulmonary arterial hypertension patients. Pulm Circ. 13:e122022023.
View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Ngala RA, Awe MA and Nsiah P: The effects
of plasma chromium on lipid profile, glucose metabolism and
cardiovascular risk in type 2 diabetes mellitus: A case-control
study. PLoS One. 13:e01979772018. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Adzhubei I, Jordan DM and Sunyaev SR:
Predicting functional effect of human missense mutations using
PolyPhen-2. Curr Protoc Hum Genet Chapter 7. Unit7 20. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
80
|
1000 Genomes Project Consortium, . Auton
A, Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO, Marchini
JL, McCarthy S, McVean GA and Abecasis GR: A global reference for
human genetic variation. Nature. 526:68–74. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Kircher M, Witten DM, Jain P, O'Roak BJ,
Cooper GM and Shendure J: A general framework for estimating the
relative pathogenicity of human genetic variants. Nat Genet.
46:310–315. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Ng PC and Henikoff S: SIFT: Predicting
amino acid changes that affect protein function. Nucleic Acids Res.
31:3812–3814. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Schwarz JM, Rodelsperger C, Schuelke M and
Seelow D: MutationTaster evaluates disease-causing potential of
sequence alterations. Nat Methods. 7:575–576. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
McNulty SN, Parikh BA, Duncavage EJ,
Heusel JW and Pfeifer JD: Optimization of population frequency
cutoffs for filtering common germline polymorphisms from tumor-only
next-generation sequencing data. J Mol Diagn. 21:903–912. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Sukhai MA, Misyura M, Thomas M, Garg S,
Zhang T, Stickle N, Virtanen C, Bedard PL, Siu LL, Smets T, et al:
Somatic tumor variant filtration strategies to optimize tumor-only
molecular profiling using targeted next-generation sequencing
panels. J Mol Diagn. 21:261–273. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Hiltemann S, Jenster G, Trapman J, van der
Spek P and Stubbs A: Discriminating somatic and germline mutations
in tumor DNA samples without matching normals. Genome Res.
25:1382–1390. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Teer JK, Zhang Y, Chen L, Welsh EA, Cress
WD, Eschrich SA and Berglund AE: Evaluating somatic tumor mutation
detection without matched normal samples. Hum Genomics. 11:222017.
View Article : Google Scholar : PubMed/NCBI
|
